سعر لوبيراسين 2مجم 6 كبسولات 2022

Loperamide hydrochloride 2 mg capsules, 6 capsules (Alexandria).

• Control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older, and of chronic diarrhea associated with inflammatory bowel disease in adults; reduction of the volume of discharge from ileostomies.Population: Adults and children 2 years and olderDailyMed (U.S. National Library of Medicine)

• Acute diarrhea trials: constipation 2.6% (placebo 0.8%). Chronic diarrhea trials: constipation 5.3% and dizziness 1.4%. Across all studies nausea, constipation and abdominal cramps were reported in about 1.4-1.8% of patients; postmarketing reports include QT/QTc prolongation and torsades de pointes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pediatric patients less than 2 years of age (risk of respiratory depression and serious cardiac adverse reactions).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to loperamide hydrochloride or any excipient; abdominal pain in the absence of diarrhea.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute dysentery (blood in stools and high fever); acute ulcerative colitis; bacterial enterocolitis caused by invasive organisms (Salmonella, Shigella, Campylobacter); pseudomembranous colitis associated with broad-spectrum antibiotics.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: torsades de pointes, cardiac arrest and sudden death have been reported with higher than recommended doses; syncope and ventricular tachycardia have occurred at recommended doses in some patients with other risk factors. Avoid in combination with QT-prolonging drugs and in patients with risk factors for torsades.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Fluid and electrolyte depletion may occur in diarrhea; give appropriate fluid and electrolyte replacement. Discontinue promptly if constipation, abdominal distension or ileus develop; stop if no improvement in acute diarrhea within 48 hours.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use with special caution in children because of greater variability of response, particularly with dehydration under 6 years; patients with AIDS should stop at early signs of abdominal distension (toxic megacolon reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4 and CYP2C8 inhibitors (itraconazole, gemfibrozil)Itraconazole increased loperamide Cmax/exposure 2.9-/3.8-fold, gemfibrozil 1.6-/2.2-fold, and the combination 4.2-/12.6-fold; monitor for cardiac adverse reactions.DailyMed (U.S. National Library of Medicine)
• P-glycoprotein inhibitors (e.g., quinidine, ritonavir)Increase loperamide plasma concentrations 2- to 3-fold; monitor for cardiac adverse reactions.DailyMed (U.S. National Library of Medicine)
• SaquinavirLoperamide decreased saquinavir exposure by 54%, which may reduce its efficacy; monitor therapeutic efficacy of saquinavir.DailyMed (U.S. National Library of Medicine)

• Animal studies showed no teratogenicity but there are no adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Small amounts of loperamide may appear in human milk; not recommended during breast-feeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Loperamide: Acts on opiate receptors in the gut wall, inhibiting peristalsis, prolonging transit time and reducing fecal volume (US label).